ArticleEuropean journal of medical research2026
Association between cardiometabolic index and stage progression in cardiovascular-kidney-metabolic syndrome: insights from a Chinese population-based cohort study.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe emerging concept of cardiovascular-kidney-metabolic syndrome (CKM) highlights the pathophysiological interconnection between cardiorenal and metabolic disorders. This study investigates the longitudinal association between the cardiometabolic index (CMI) and CKM stage progression. METHODS AND
resultsThis study utilized data from the China Health and Retirement Longitudinal Study. The baseline CMI was computed utilizing the triglycerides-to-high-density lipoprotein cholesterol ratio multiplied by the waist-to-height ratio. CKM is defined and categorized into five stages (0-4) based on metabolic, cardiovascular, and renal disorders. We evaluated the impact of CMI on the CKM stage progression from Wave 1(2011) to Wave 3(2015). Multivariable logistic regression and restricted cubic spline (RCS) models were constructed to illustrate the relationship between CMI and CKM stage progression. A total of 4080 patients were included. The rate of CKM progression to advanced stages significantly increased with higher CMI quartiles. When entered into the multivariable logistic regressions as a continuous variable, elevated CMI was a remarkable predictor for progression to CKM stages 2-4 among participants at baseline CKM stages 0-1 [OR(95%CI) 1.66 (1.32-2.11)], progression to CKM stages 3-4 among those at baseline CKM stages 0-2 [OR(95%CI) 1.14 (1.03-1.26)], and progression to CKM stage 4 among those at baseline CKM stages 0-3 [OR(95%CI) 1.13 (1.00-1.28)], after adjustment for potential confounders. This association persisted when CMI was modeled as a categorical variable. RCS analysis demonstrated significant positive associations between elevated CMI levels and an increased risk of progression to advanced CKM stages (all P < 0.05).
conclusionElevated CMI is significantly associated with CKM stage progression over time. CMI could act as a simple, useful tool for the risk assessment of CKM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.